Benitec Biopharma Inc. (BNTC) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Hayward, CA, アメリカ. 現CEOは Jerel A. Banks.
BNTC を有する IPO日 2014-06-24, 16 名の正社員, に上場 NASDAQ Capital Marke, 時価総額 $347.77M.
Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.
